UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tropism Switching Is Rare in Aviremic HIV-Infected Patients Virologically Suppressed With Non–Entry-Inhibiting Antiretroviral Regimens

The Annals of pharmacotherapy, 2020-12, Vol.54 (12), p.1263-1264

2020

Volltextzugriff (PDF)

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES

AIDS research and human retroviruses, 2013-02, Vol.29 (2), p.350-358

2013

Volltextzugriff (PDF)

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

The Lancet (British edition), 2017-09, Vol.390 (10101), p.1499-1510

2017

Volltextzugriff (PDF)

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

The Journal of infectious diseases, 2013-03, Vol.207 (5), p.740-748

2013

Volltextzugriff (PDF)

Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

AIDS (London), 2011-09, Vol.25 (14), p.1737-1745

2011

Volltextzugriff (PDF)

Clinical and Morphologic Findings in Disseminated Scedosporium Apiospermum Infections in Immunocompromised Patients

Proceedings - Baylor University. Medical Center, 2014-07, Vol.27 (3), p.253-256

2014

Volltextzugriff (PDF)

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758

AIDS research and human retroviruses, 2009-04, Vol.25 (4), p.395-403

2009

Volltextzugriff (PDF)

Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load

European journal of immunology, 2014-09, Vol.44 (9), p.2802-2810

2014

Volltextzugriff (PDF)

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

AIDS (London), 2009-07, Vol.23 (12), p.1547-1556

2009

Volltextzugriff (PDF)

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1429-1441

2008

Volltextzugriff (PDF)

Central Nervous System Tuberculosis

Proceedings - Baylor University. Medical Center, 2010-10, Vol.23 (4), p.359-360

2010

Volltextzugriff (PDF)

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

Antiviral therapy, 2015-01, Vol.20 (3), p.343-348

2015

Volltextzugriff (PDF)

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

The New England journal of medicine, 2008-10, Vol.359 (14), p.1442-1455

2008

Volltextzugriff (PDF)

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

Journal of acquired immune deficiency syndromes (1999), 2009-06, Vol.51 (2), p.163-174

2009

Volltextzugriff (PDF)

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

The lancet HIV, 2017-12, Vol.4 (12), p.e536-e546

2017

Volltextzugriff (PDF)

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells

AIDS (London), 2013-08, Vol.27 (13), p.2041-2051

2013

Volltextzugriff (PDF)

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

BMC infectious diseases, 2013-06, Vol.13 (1), p.269-269, Article 269

2013

Volltextzugriff (PDF)

Primary Effusion Lymphoma Diagnosed by Pericardiocentesis

Proceedings - Baylor University. Medical Center, 2009-01, Vol.22 (1), p.77-80

2009

Volltextzugriff (PDF)

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4 super(+) and CD8 super(+) T cells

AIDS (London), 2013-08, Vol.27 (13), p.2041-2051

2013

Volltextzugriff (PDF)

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

Journal of immunological methods, 2011-02, Vol.365 (1-2), p.27-37

2011

Volltextzugriff (PDF)

Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730

AIDS research and human retroviruses, 2010-08, Vol.26 (8), p.841-845

2010

Volltextzugriff (PDF)

Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study

Open forum infectious diseases, 2016-12, Vol.3 (suppl_1)

2016

Volltextzugriff (PDF)

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients

Retrovirology, 2012-09, Vol.9 (S2), p.P328-P328, Article P328

2012

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(104)
Mit Volltextzugriff
(132)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tropism Switching Is Rare in Aviremic HIV-Infected Patients Virologically Suppressed With Non–Entry-Inhibiting Antiretroviral Regimens

Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Antiviral activity, safety, and pharmacokinetics/ pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Clinical and Morphologic Findings in Disseminated Scedosporium Apiospermum Infections in Immunocompromised Patients

Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758

Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/ emtricitabine with lopinavir/ritonavir for initial HIV treatment

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Central Nervous System Tuberculosis

Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients

Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4+ and CD8+ T cells

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results

Primary Effusion Lymphoma Diagnosed by Pericardiocentesis

Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial

Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4 super(+) and CD8 super(+) T cells

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

Short communication: Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine + tenofovir DF in antiretroviral-naïve, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730

Efficacy and Safety of Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate in HIV-infected, Virologically Suppressed Black and Non-Blacks Adults Through Week 48: Subgroup Analysis of a Randomized Switch Study

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients

Aktive Filter

Suchergebnisse filtern